{"entity":{"id":"nct07481786","kind":"trial","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","aka":[],"tldr":"A phase 3 trial of bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.","summary":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases is a phase 3, randomised interventional study registered as NCT07481786 by Sun Yat-sen University, with a registry enrolment figure of 220 participants, started 2026-03-20 and due to reach its primary completion in 2029-09-15. Interventions recorded: FSRT; HA-WBRT-SIB; Bevacizumab. Conditions listed: Lung Adenocarcinoma; Brain Metastases; Radiotherapy, Intensity-Modulated; Bevacizumab; Whole-Brain Radiotherapy. Primary outcome: Intracranial Progression-Free Survival (IPFS); Neurocognitive Function failure. Lung eligibility wording from the registry: \"* Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07481786","url":"https://clinicaltrials.gov/study/NCT07481786"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody","sbrt"],"targets":[],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07481786","phase":"3","setting":"Application of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy (FSRT-Bev) Versus Hippocampus-Avoidant Whole-Brain Radiotherapy With Simultaneous Integrated Boost (HA-WBRT-SIB) in Patients With Extensive Brain Metastases From Lung Adenocarcinoma: A Phase III Randomized Controlled Trial Evaluating Intracranial Control Efficacy and Neurocognitive Function","sponsor":"Sun Yat-sen University","enrolled":220,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07481786/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}